Fredun [FREDUN] vs Aarti Drugs [AARTIDRUGS] Detailed Stock Comparison
Fredun
BSE
Loading...
Aarti Drugs
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Fredun wins in 10 metrics, Aarti Drugs wins in 10 metrics, with 0 ties. Both stocks appear equally matched on key metrics.
View Metrics Details
Vital Metrics Comparison
| Metric | Fredun | Aarti Drugs | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 21.05 | 23.59 | Fredun |
| Price-to-Book Ratio | 3.30 | 3.25 | Aarti Drugs |
| Debt-to-Equity Ratio | 118.22 | 44.92 | Aarti Drugs |
| PEG Ratio | 0.63 | 0.37 | Aarti Drugs |
| EV/EBITDA | 10.78 | 17.02 | Fredun |
| Profit Margin (TTM) | 4.50% | 7.80% | Aarti Drugs |
| Operating Margin (TTM) | 12.99% | 10.11% | Fredun |
| EBITDA Margin (TTM) | 12.99% | 10.11% | Fredun |
| Return on Equity | 13.96% | 12.28% | Fredun |
| Return on Assets (TTM) | 4.05% | 6.53% | Aarti Drugs |
| Free Cash Flow (TTM) | $-351.69M | $674.20M | Aarti Drugs |
| Dividend Yield | 0.09% | 0.22% | Aarti Drugs |
| 1-Year Return | 30.92% | -2.04% | Fredun |
| Price-to-Sales Ratio (TTM) | 1.01 | 1.83 | Fredun |
| Enterprise Value | $6.61B | $50.34B | Aarti Drugs |
| EV/Revenue Ratio | 1.33 | 2.08 | Fredun |
| Gross Profit Margin (TTM) | 26.25% | 36.77% | Aarti Drugs |
| Revenue per Share (TTM) | $1,128 | $265 | Fredun |
| Earnings per Share (Diluted) | $50.32 | $20.63 | Fredun |
| Beta (Stock Volatility) | 0.84 | 0.21 | Aarti Drugs |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Fredun vs Aarti Drugs Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Fredun | 0.82% | -2.86% | 16.92% | 52.88% | 50.84% | 42.65% |
| Aarti Drugs | 3.53% | -3.86% | 1.23% | 5.23% | 18.26% | 6.84% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Fredun | 30.92% | 8.95% | 351.36% | 8,277.20% | 8,277.20% | 8,277.20% |
| Aarti Drugs | -2.04% | 8.97% | -37.88% | 208.08% | 2,669.78% | 2,338.13% |
Performance & Financial Health Analysis: Fredun vs Aarti Drugs
| Metric | FREDUN | AARTIDRUGS |
|---|---|---|
| Market Information | ||
| Market Cap | ₹5.00B | ₹44.42B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 26,613 | 159,509 |
| 90 Day Avg. Volume | 21,414 | 613,674 |
| Last Close | ₹1,055.75 | ₹503.85 |
| 52 Week Range | ₹635.00 - ₹1,143.00 | ₹312.00 - ₹635.00 |
| % from 52W High | -7.63% | -20.65% |
| All-Time High | ₹1,428.00 (Dec 05, 2022) | ₹1,026.95 (Oct 05, 2020) |
| % from All-Time High | -26.07% | -50.94% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.52% | 0.06% |
| Quarterly Earnings Growth | 0.64% | 0.62% |
| Financial Health | ||
| Profit Margin (TTM) | 0.05% | 0.08% |
| Operating Margin (TTM) | 0.13% | 0.10% |
| Return on Equity (TTM) | 0.14% | 0.12% |
| Debt to Equity (MRQ) | 118.22 | 44.92 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹321.10 | ₹149.84 |
| Cash per Share (MRQ) | ₹12.65 | ₹2.48 |
| Operating Cash Flow (TTM) | ₹-1,140,997,000 | ₹2.83B |
| Levered Free Cash Flow (TTM) | ₹197.39M | ₹1.68B |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.09% | 0.22% |
| Last 12-Month Dividend | ₹0.70 | ₹1.00 |
Valuation & Enterprise Metrics Analysis: Fredun vs Aarti Drugs
| Metric | FREDUN | AARTIDRUGS |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 21.05 | 23.59 |
| Forward P/E | N/A | 14.97 |
| PEG Ratio | 0.63 | 0.37 |
| Price to Sales (TTM) | 1.01 | 1.83 |
| Price to Book (MRQ) | 3.30 | 3.25 |
| Market Capitalization | ||
| Market Capitalization | ₹5.00B | ₹44.42B |
| Enterprise Value | ₹6.61B | ₹50.34B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.33 | 2.08 |
| Enterprise to EBITDA | 10.78 | 17.02 |
| Risk & Other Metrics | ||
| Beta | 0.84 | 0.21 |
| Book Value per Share (MRQ) | ₹321.10 | ₹149.84 |
Financial Statements Comparison: Fredun vs Aarti Drugs
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | FREDUN | AARTIDRUGS |
|---|---|---|
| Revenue/Sales | ₹1.19B | ₹6.77B |
| Cost of Goods Sold | ₹880.59M | ₹4.37B |
| Gross Profit | ₹313.44M | ₹2.40B |
| Research & Development | ₹0 | N/A |
| Operating Income (EBIT) | ₹155.72M | ₹784.50M |
| EBITDA | ₹169.91M | ₹951.90M |
| Pre-Tax Income | ₹90.40M | ₹711.50M |
| Income Tax | ₹22.75M | ₹83.80M |
| Net Income (Profit) | ₹67.66M | ₹627.70M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | FREDUN | AARTIDRUGS |
|---|---|---|
| Cash & Equivalents | ₹6.37M | ₹45.80M |
| Total Current Assets | ₹4.28B | ₹13.38B |
| Total Current Liabilities | ₹3.21B | ₹8.37B |
| Long-Term Debt | ₹165.35M | ₹2.86B |
| Total Shareholders Equity | ₹1.41B | ₹13.69B |
| Retained Earnings | N/A | N/A |
| Property, Plant & Equipment | ₹524.89M | ₹8.59B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | FREDUN | AARTIDRUGS |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | FREDUN | AARTIDRUGS |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 26,613 | 159,509 |
| Average Daily Volume (90 Day) | 21,414 | 613,674 |
| Shares Outstanding | 4.72M | 91.27M |
| Float Shares | 2.71M | 35.46M |
| % Held by Insiders | 0.59% | 0.61% |
| % Held by Institutions | 0.00% | 0.11% |
Dividend Analysis & Yield Comparison: Fredun vs Aarti Drugs
| Metric | FREDUN | AARTIDRUGS |
|---|---|---|
| Last 12-Month Dividend | ₹0.70 | ₹1.00 |
| Last 12-Month Dividend Yield | 0.09% | 0.22% |
| 3-Year Avg Annual Dividend | ₹0.70 | ₹1.00 |
| 3-Year Avg Dividend Yield | 0.08% | 0.23% |
| 3-Year Total Dividends | ₹2.10 | ₹3.00 |
| Ex-Dividend Date | Sep 23, 2024 | Feb 04, 2025 |